Mariesa Beth Coppola
Direktor/Vorstandsmitglied bei Albany Molecular Research (UK) Ltd.
Profil
Mariesa Beth Coppola is currently a Director at Gadea Grupo Farmacéutico SL, Albany Molecular Research (UK) Ltd., and Albany Molecular Research (Glasgow) Ltd.
He previously worked as a Co-Managing Director at Euticals GmbH.
Aktive Positionen von Mariesa Beth Coppola
| Unternehmen | Position | Beginn |
|---|---|---|
Albany Molecular Research (UK) Ltd.
 Albany Molecular Research (UK) Ltd. Pharmaceuticals: MajorHealth Technology Albany Molecular Research (UK) Ltd. manufacture of pharmaceutical preparations. The company is headquartered in Holywell, the United Kingdom. | Direktor/Vorstandsmitglied | 04.12.2017 |
Albany Molecular Research (Glasgow) Ltd.
 Albany Molecular Research (Glasgow) Ltd. Pharmaceuticals: MajorHealth Technology Albany Molecular Research (Glasgow) Ltd. is based in Glasgow, UK. Part of Curia Global, Inc., Albany Molecular Research (Glasgow) Ltd. is a British company that provides pharmaceutical development services. The company was founded in 1997. Albany Molecular Research (Glasgow was acquired by Curia Global, Inc. from Aptuit LLC on January 09, 2015 for $24 million. | Direktor/Vorstandsmitglied | 20.02.2018 |
Gadea Grupo Farmacéutico SL
 Gadea Grupo Farmacéutico SL Pharmaceuticals: MajorHealth Technology Gadea Grupo Farmacéutico SL is a pharmaceutical company. It is engaged in manufacturing general APIs, steroids, sex hormones, sterile filtration products, and others. The company was founded by Gerardo Gutierrez Fuentes in 1991 and is headquartered in Boecillo, Spain. | Direktor/Vorstandsmitglied | 07.11.2018 |
Ehemalige bekannte Positionen von Mariesa Beth Coppola
| Unternehmen | Position | Ende |
|---|---|---|
Curia Germany GmbH
 Curia Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Curia Global, Inc., Curia Germany GmbH is a company that specializes in Active Pharmaceutical Ingredients & Intermediates. The company is based in Frankfurt, Germany. The company provides quality products, reliably and responsibly applying the world's most difficult chemical technologies. The company was founded in 2006 and the CEOs are Joachim Kaus and Thomas Randall. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Gadea Grupo Farmacéutico SL
Gadea Grupo Farmacéutico SL Pharmaceuticals: MajorHealth Technology Gadea Grupo Farmacéutico SL is a pharmaceutical company. It is engaged in manufacturing general APIs, steroids, sex hormones, sterile filtration products, and others. The company was founded by Gerardo Gutierrez Fuentes in 1991 and is headquartered in Boecillo, Spain. | Health Technology |
Albany Molecular Research (UK) Ltd.
Albany Molecular Research (UK) Ltd. Pharmaceuticals: MajorHealth Technology Albany Molecular Research (UK) Ltd. manufacture of pharmaceutical preparations. The company is headquartered in Holywell, the United Kingdom. | Health Technology |
Albany Molecular Research (Glasgow) Ltd.
Albany Molecular Research (Glasgow) Ltd. Pharmaceuticals: MajorHealth Technology Albany Molecular Research (Glasgow) Ltd. is based in Glasgow, UK. Part of Curia Global, Inc., Albany Molecular Research (Glasgow) Ltd. is a British company that provides pharmaceutical development services. The company was founded in 1997. Albany Molecular Research (Glasgow was acquired by Curia Global, Inc. from Aptuit LLC on January 09, 2015 for $24 million. | Health Technology |
Curia Germany GmbH
Curia Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Curia Global, Inc., Curia Germany GmbH is a company that specializes in Active Pharmaceutical Ingredients & Intermediates. The company is based in Frankfurt, Germany. The company provides quality products, reliably and responsibly applying the world's most difficult chemical technologies. The company was founded in 2006 and the CEOs are Joachim Kaus and Thomas Randall. | Health Technology |